Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FDJK7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,247
Award facts
- Contract value 100% obligated
- $20,247.27 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. Awarded on January 6, 2026, with a ceiling value of $20,247.27, this firm fixed-price delivery order is set to be completed by January 7, 2026. The award carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a comprehensive $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical pharmaceutical supplier within the federal military medical supply chain, leveraging its established capabilities to distribute a broad portfolio of branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables. The company's PPV-G GEN V contract, awarded November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor supporting recurring medical supply needs across the Department of Defense healthcare system globally.
Quick answers
Who was awarded contract SPE2DR26FDJK7?
SPE2DR26FDJK7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FDJK7 worth?
The government has obligated $20,247 on SPE2DR26FDJK7.
Is contract SPE2DR26FDJK7 an order under another contract?
Yes. SPE2DR26FDJK7 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJK7 competed?
The extent of competition for SPE2DR26FDJK7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award